Silk Road Medical (NASDAQ:SILK) and Nephros (OTCMKTS:NEPHD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
This table compares Silk Road Medical and Nephros’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Silk Road Medical||N/A||N/A||N/A|
Earnings & Valuation
This table compares Silk Road Medical and Nephros’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Silk Road Medical||$34.56 million||31.24||-$37.63 million||N/A||N/A|
|Nephros||$5.69 million||8.42||-$3.40 million||($0.54)||-11.57|
Nephros has lower revenue, but higher earnings than Silk Road Medical.
This is a summary of recent recommendations for Silk Road Medical and Nephros, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Silk Road Medical||0||1||4||0||2.80|
Silk Road Medical currently has a consensus target price of $44.80, suggesting a potential upside of 27.64%. Given Silk Road Medical’s higher probable upside, equities analysts plainly believe Silk Road Medical is more favorable than Nephros.
Institutional and Insider Ownership
70.2% of Silk Road Medical shares are held by institutional investors. 6.8% of Nephros shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Silk Road Medical beats Nephros on 8 of the 10 factors compared between the two stocks.
About Silk Road Medical
Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.
Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.